



Curriculum Vitae

Christoph Wanner, M.D. Professor of Medicine,
Head of Nephrology, Department of Medicine, University Hospital
Oberduerrbacherstr 6, 97080 Würzburg, Germany
Tel.: +49-931-201 39030, FAX: +49-931-201 639300
E-mail: wanner_c@ukw.de <http://www.uni-wuerzburg.de/nephrologie>

Curriculum vitae

- Born 21.03.1957, Bad Mergentheim, Germany
- 1976-1982 Education in Medicine at the Universities of Ferrara (Italy), Berlin and Würzburg
- 1982 Subinternships, Anaesthesia & Int Med, Singapore and Zürich
- 1983 Thesis (degree of M.D.) at the Department of Medicine, University of Würzburg, Germany
- 1983-1990 Residency and Fellowship in Internal Medicine and Nephrology at the Department of Medicine, Division of Nephrology, University of Freiburg, Germany
- 1990 Habilitation (equivalent to PhD), Faculty member, Assistant Professor at the Department of Medicine, Division of Nephrology, University of Freiburg
- 1991 German Board of Internal Medicine Examination
- 1992 National Institutes of Health, National Heart, Lung, and Blood

- Institute, Molecular Disease Branch
- 1993 German Board of Internal Medicine/Nephrology Examination
- 1994 since Professor of Medicine, Department of Medicine, Division of Nephrology, University of Würzburg**
- 2003-2009 Director, Clinical Trial Service Unit, University Hospital of Würzburg

Research Profile

Scientific Areas of Interest

- 1990- Role of lipids in the progression of renal disease; glomerulosclerosis & atherosclerosis in CKD and kidney failure
- 1998-2005: Principal investigator of the 4D study
 - 2003-2011: Central Europe Coordinator of SHARP
 - 2011-2017: Germany Coordinator of REVEAL
- 1996- Elucidation of the inflammatory response syndrome and biomarkers in diabetic kidney disease, CKD and kidney failure
- 2000- Fabry disease and Fabry nephropathy
- 2008- Cardiovascular and renal outcomes in Type 2 Diabetes
- Since 2010: Steering committees of BEACON, EMPA-REG OUTCOME, CARMELINA, EMPA-KIDNEY & ASCEND studies
- 2009- Cardio-Renal Crosstalk and heart failure: since 2016 Steering committee of EMPEROR studies.

Leadership in Professional Societies

- 1998-2007 Councilor, German Society of Nephrology
- 1998-2007 Chairman, Kuratorium of the Germany Society of Nephrology
- 2003-2007 President, German Kidney Foundation
- 2006-09 & 2018-21 Councilor, European Renal Association – ERA-EDTA
- 2012-2014 President, Int Soc Renal Nutrition & Metabolism (ISRNM)
- 2009-2015 Chairman, ERA-EDTA Renal Registry
- 2020-2023 President, European Renal Association - ERA-EDTA

Editorial scientific activities

- 2002-2004 American Journal Kidney Disease (*Associate Editor*)
- 2003-2008 *Editor-in-chief*: Kidney & Blood Pressure Research
- 2017-2020 Associate Editor: Clinical Journal of the Am Soc Nephrology
- 2011-2019 *Editor-in-chief*: Journal of Renal Nutrition

Advisory board member and review activities

- 2000-2006 K/DOQI, Kidney Disease Outcomes Quality Initiative:
- 2003-2019 KDIGO, Executive Board of Directors (2003-2006, 2011-2017)

Awards

- 2007 International Distinguished Medal of the US NKF

2011	Honorary Member, Polish Society of Nephrology
2012	Doctor Honoris Causa, Charles University Prague
2016	ERA-EDTA Outstanding Clinical Contributions to Nephrology
2018	Honorary Int Member, Japanese Society of Nephrology
2018	Franz-Volhard-Medaille, DGfN
2020	Honorary Member, Hungarian Society of Nephrology

Publications in the respective field

- Hirsch factor 86 (Web of Science); cumulative IF >2000; >39.000 citations (>5200 in 2019)
- >750 citations in pubmed (>16 in NEJM, Lancet & JAMA), >50 books and book chapters

10 Selected publications

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;353:238-248

Baigent C, Landray M, Reith C, Emberson J, Wheeler DC, Tomson C, **Wanner C** et al. SHARP Investigators. The effect of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a placebo controlled trial. *Lancet* 2011;377:2181-219

Thadani R, Appelbaum E, Pritchett Y, Chang Y, Wegner J, Bhan I, Agarwal R, Zoccali C, **Wanner C**, et al. Vitamin D therapy and cardiac structure, function, and cardiovascular events. *JAMA* 2012;307:674-684

deZeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, **Wanner C**, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med* 2013;369:2492-2503

Zinman B, **Wanner C**, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen O-E, Woerle HJ, Broedl UC, Inzucchi S. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. *New Engl J Med* 2015;373:2117-2128

Wanner C, Inzucchi S, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen O-E, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. *New Engl J Med* 2016;375:323-334

Wanner C, Amman K, Shoji T. The heart and vascular system in dialysis. *Lancet* 2016;388:276-284

Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. *Circulation* 2018;137:119-129

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedle UC, von Eynatten M, Groop PH. Empagliflozin and kidney function decline in patients with type 2 diabetes. A slope analysis from the EMPA-REG OUTCOME trial. *J Am Soc Nephrol* 2018;29:2755-2769

Packer M, Anker SD, Butler J et al, **Wanner C**, Zannad F. EMPEROR-Reduced trial. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:1413-1424